Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II
Open Access
- 14 October 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (4), 79
- https://doi.org/10.3390/ijns6040079
Abstract
Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, is a lysosomal storage disorder (LSD) caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). MPS II satisfies all criteria defined by the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) for inclusion in the Recommended Uniform Screening Panel (RUSP) for newborn screening, apart from the fact that only minimal prospective population screening data are available. This report details the analytical validation, clinical validation, and implementation of a fluorometric assay for measurement of IDS activity in newborn dried blood spot (DBS) specimens at the Missouri State Public Health Laboratory (MSPHL). The assay is performed in a microwell plate format requiring approximately 15 min of hands-on time per plate and an incubation time of two hours. The analytical validation of this assay included linearity, analytical sensitivity, precision, and carry-over testing. Clinical validation was completed using more than 5000 deidentified presumptive normal newborn DBS specimens as well as seven specimens from patients known to be affected with MPS II. Following validation, MSPHL began prospective screening using the IDS assay on 1 November 2018. In the first 18 months of screening (to 30 June 2020), 146,954 specimens were prospectively screened using the method. Two newborns were identified with severe Hunter syndrome and the assay had a presumptive positive rate of 0.022%.Keywords
This publication has 14 references indexed in Scilit:
- Incidence of 4 Lysosomal Storage Disorders From 4 Years of Newborn ScreeningJAMA Pediatrics, 2018
- Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in TaiwanOrphanet Journal of Rare Diseases, 2018
- Effectiveness of Early Hematopoietic Stem Cell Transplantation in Preventing Neurocognitive Decline in Mucopolysaccharidosis Type II: A Case SeriesPublished by Springer Science and Business Media LLC ,2018
- Italian guidelines on the assessment and management of pediatric head injury in the emergency departmentItalian Journal of Pediatrics, 2018
- Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7 years follow-upMolecular Genetics and Metabolism Reports, 2017
- Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome)Expert Opinion on Orphan Drugs, 2017
- Clinical outcomes after 3 years of idursulfase treatment in patients with MPS II: data from the Hunter Outcome Survey (HOS)Molecular Genetics and Metabolism, 2017
- Enzymatic replacement therapy for Hunter disease: Up to 9years experience with 17 patientsMolecular Genetics and Metabolism Reports, 2015
- Lysosomal Storage Disorder Screening Implementation: Findings from the First Six Months of Full Population Pilot Testing in MissouriThe Journal of Pediatrics, 2015
- A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patientsKorean Journal of Pediatrics, 2012